(IBDX) iShares Trust - iShares - Ratings and Ratios
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US46436E3128 • Target Maturity
IBDX: Fixed, Income, Securities, Corporate, Bonds
The iShares iBonds Dec 2032 Term Corporate ETF (IBDX) is designed to provide exposure to investment-grade corporate bonds with a specific maturity target of December 2032. This ETF is part of a series of target maturity funds, each tied to a specific year, allowing investors to align their fixed-income exposure with their investment horizon. The fund is structured to hold bonds until they mature, which can reduce uncertainty for investors seeking predictable income streams.
IBDX primarily invests in U.S. dollar-denominated, investment-grade corporate bonds. While its core focus is on U.S. issuers, it may also include bonds from non-U.S. issuers to ensure it tracks its underlying index effectively. The fund is non-diversified, meaning it can concentrate its investments in fewer securities compared to diversified funds. This approach allows for tighter tracking of the index but may also increase certain risks.
The ETF is managed by BlackRock Fund Advisors (BFA), which employs a passive indexing strategy to track the performance of the Bloomberg Barclays U.S. Corporate Index. At least 80% of the funds assets are allocated to securities included in the index, and at least 90% are invested in fixed-income securities of the types represented in the index. This structured approach helps maintain consistency with the underlying indexs performance.
With an AUM of approximately $972 million, IBDX offers a cost-effective way to gain exposure to a diversified portfolio of corporate bonds maturing in 2032. The funds target maturity feature makes it particularly appealing to investors seeking to manage interest rate risk more effectively, as the ETFs duration will naturally decrease as it approaches its maturity date.
Investors should note that while the fund provides a straightforward way to access a maturing corporate bond portfolio, it does not offer the same diversification benefits as broader fixed-income funds. As with any investment-grade corporate bond ETF, credit risk remains a consideration, though the focus on higher-quality issuers helps mitigate this to some extent.
Additional Sources for IBDX ETF
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
IBDX ETF Overview
Market Cap in USD | 1,011m |
Category | Target Maturity |
TER | 0.10% |
IPO / Inception | 2022-06-28 |
IBDX ETF Ratings
Growth 5y | 40.7% |
Fundamental | - |
Dividend | 66.7% |
Rel. Strength Industry | -2.75 |
Analysts | - |
Fair Price Momentum | 24.50 USD |
Fair Price DCF | - |
IBDX Dividends
Dividend Yield 12m | 4.60% |
Yield on Cost 5y | 5.11% |
Annual Growth 5y | 28.83% |
Payout Consistency | 100.0% |
IBDX Growth Ratios
Growth Correlation 3m | 61.9% |
Growth Correlation 12m | 70.3% |
Growth Correlation 5y | 82.6% |
CAGR 5y | 4.28% |
CAGR/Max DD 5y | 0.34 |
Sharpe Ratio 12m | 0.14 |
Alpha | 0.36 |
Beta | 0.18 |
Volatility | 5.05% |
Current Volume | 195.4k |
Average Volume 20d | 184.6k |
As of March 14, 2025, the stock is trading at USD 24.81 with a total of 195,400 shares traded.
Over the past week, the price has changed by -0.28%, over one month by +0.98%, over three months by +0.80% and over the past year by +5.27%.
Partly, yes. Based on ValueRay Analyses, iShares Trust - iShares (NYSE ARCA:IBDX) is currently (March 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 40.73 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of IBDX as of March 2025 is 24.50. This means that IBDX is currently overvalued and has a potential downside of -1.25%.
iShares Trust - iShares has no consensus analysts rating.
According to ValueRays Forecast Model, IBDX iShares Trust - iShares will be worth about 26.5 in March 2026. The stock is currently trading at 24.81. This means that the stock has a potential upside of +6.77%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 26.5 | 6.8% |